MedTrace Logo

Identification of a New Metabolite of Furosemide in Humans

NCT02872168 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2016-08-19

No results posted yet for this study

Summary

Recent in-vitro and in-vivo studies performed by one of the investigators (ESO, ICMPE, UPEC, France) have recently allowed to synthetize a new and easy-to-synthesized chemical compound of the furosemide (pyridinium furosemide) during furosemide degradation by electro-Fenton or bioconversion. The biological properties of pyridinium furosemide are currently under investigation. Furosemide is a diuretics currently used in the treatment of patients with heart failure. The goal of the investigators is to assay pyridinium furosemide in urine of patients treated by furosemide to demonstrate that pyridinium is or not a metabolite of furosemide in humans. This study will contribute to assess the fate of pharmaceutical residues of furosemide in the environment.

Conditions

  • Treatment by Furosemide

Interventions

OTHER

Not intervention

None. there is no modification in the treatment of patients. A urine collection is carry out in patients during the day of their enrolment.

Sponsors & Collaborators

  • Henri Mondor University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2016-02-29
Completion
2016-02-29

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02872168 on ClinicalTrials.gov